|Mar 08, 2017||CTI BioPharma to Present at the 29th Annual ROTH Conference|
|SEATTLE, March 8, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 3:30 p.m. PT/6:30 p.m. ET in Dana Point, CA.
The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.
About CTI BioPharma
CTI BioPharma Corp. is a biopharmaceutica... |
|Mar 02, 2017||CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results|
|SEATTLE, March 2, 2017 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2016.
"The presentation of detailed results from the Phase 3 PERSIST-2 trial of pacritinib at the ASH Annual Meeting in December demonstrated that pacritinib may have potential to address a critical unmet need for myelofibrosis patients with low blood platelets or those ineligible to receive, intolerant of or which have insu... |
|Feb 27, 2017||CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO|
|SEATTLE, Feb. 27, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced the appointment of Adam Craig, M.D., Ph.D., as President and Chief Executive Officer (CEO) and member of the Board of Directors effective March 20, 2017. Dr. Craig succeeds Richard Love, interim President and CEO who will continue to serve on the company's Board of Directors. Dr. Craig has over 20 years of experience in hematology, oncology and drug development in both the US and Eu... |